LT3060256T - Nauja stabili kompozicija - Google Patents

Nauja stabili kompozicija

Info

Publication number
LT3060256T
LT3060256T LTEP14786915.0T LT14786915T LT3060256T LT 3060256 T LT3060256 T LT 3060256T LT 14786915 T LT14786915 T LT 14786915T LT 3060256 T LT3060256 T LT 3060256T
Authority
LT
Lithuania
Prior art keywords
stable formulation
novel stable
novel
formulation
stable
Prior art date
Application number
LTEP14786915.0T
Other languages
English (en)
Inventor
Carsten Olbrich
Thomas Trill
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of LT3060256T publication Critical patent/LT3060256T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
LTEP14786915.0T 2013-10-25 2014-10-21 Nauja stabili kompozicija LT3060256T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13190276 2013-10-25
PCT/EP2014/072558 WO2015059147A1 (en) 2013-10-25 2014-10-21 A novel stable formulation

Publications (1)

Publication Number Publication Date
LT3060256T true LT3060256T (lt) 2019-07-10

Family

ID=49552164

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14786915.0T LT3060256T (lt) 2013-10-25 2014-10-21 Nauja stabili kompozicija

Country Status (15)

Country Link
US (2) US20160250349A1 (lt)
EP (1) EP3060256B1 (lt)
JP (1) JP6813355B2 (lt)
CY (1) CY1121791T1 (lt)
DK (1) DK3060256T3 (lt)
ES (1) ES2735645T3 (lt)
HR (1) HRP20191053T1 (lt)
HU (1) HUE045020T2 (lt)
LT (1) LT3060256T (lt)
PL (1) PL3060256T3 (lt)
PT (1) PT3060256T (lt)
RS (1) RS58856B1 (lt)
SI (1) SI3060256T1 (lt)
TR (1) TR201909034T4 (lt)
WO (1) WO2015059147A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
HUE056858T2 (hu) * 2017-01-19 2022-03-28 Bayer Pharma AG Új, stabil FXIa ellenanyag-készítmény
SG11202000996UA (en) 2017-08-23 2020-03-30 Daiichi Sankyo Co Ltd Antibody-drug conjugate preparation and lyophilization for same
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
WO2023230098A1 (en) 2022-05-23 2023-11-30 Logicbio Therapeutics, Inc. Gene therapy compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110498A2 (en) * 2003-05-14 2004-12-23 Immunogen, Inc. Drug conjugate composition
EP1917030A4 (en) * 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
AU2012244675B2 (en) * 2011-04-21 2017-06-29 Seattle Genetics, Inc. Novel binder-drug conjugates (ADCs) and their use
CA2831572C (en) * 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AR086823A1 (es) * 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos

Also Published As

Publication number Publication date
DK3060256T3 (da) 2019-07-29
RS58856B1 (sr) 2019-07-31
TR201909034T4 (tr) 2019-07-22
JP2016534062A (ja) 2016-11-04
WO2015059147A1 (en) 2015-04-30
JP6813355B2 (ja) 2021-01-13
HUE045020T2 (hu) 2019-12-30
SI3060256T1 (sl) 2019-08-30
US20190240345A1 (en) 2019-08-08
PT3060256T (pt) 2019-07-19
CY1121791T1 (el) 2020-07-31
EP3060256A1 (en) 2016-08-31
EP3060256B1 (en) 2019-05-08
US20160250349A1 (en) 2016-09-01
PL3060256T3 (pl) 2019-10-31
ES2735645T3 (es) 2019-12-19
HRP20191053T1 (hr) 2019-09-20

Similar Documents

Publication Publication Date Title
HRP20182196T1 (hr) Dispenzer
EP3065716C0 (en) FORMULATIONS
GB201317990D0 (en) A conncetor
GB201319792D0 (en) Formulations
HK1224228A1 (zh) 新型製劑
GB201320432D0 (en) Novel formulation
HK1214951A1 (zh) 眼用製劑
GB2515360B (en) Dispenser
SI3060256T1 (sl) Nova stabilna formulacija
GB201322948D0 (en) Improved formulation
HK1215233A1 (zh) 分配器
GB2517232B (en) Formulation
GB201317718D0 (en) Novel formulation
HK1209981A1 (en) Formulation
IL244316A0 (en) A new composition of a drug
GB201317717D0 (en) Novel formulation
GB201312347D0 (en) Formulation
GB201312761D0 (en) A composition
ZA201405024B (en) Dispenser
GB201319398D0 (en) A footgauge
GB201306657D0 (en) Trestle
GB201316534D0 (en) Dispenser
GB201313662D0 (en) A footgauge
GB201309977D0 (en) A sausepan
GB201305769D0 (en) Dispenser